DiCE Molecules Funding & Investors
Founded in 2013, DiCE Molecules develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its core technology was invented by Stanford Professor Pehr Harbury, a 2005 recipient of the Macarthur ''genius'' award. In addition to Professor Harbury, the founding team includes Dr. Phil Patten, formerly of Maxygen, Achaogen, and DuPont, who serves as our Chief Scientific Officer; Dr. John Bedbrook, a renowned serial entrepreneur in the agricultural biotechnology space, who is the Chairman of the DiCE Board of Directors; and Dr. Kevin Judice, who served various leadership roles at Genentech, Theravance, and Achaogen prior to joining DiCE as CEO.
dicemolecules.comTotal Amount Raised: $532,381,888
DiCE Molecules Funding Rounds
Post Ipo Equity
$345,000,000
Series C
$60,000,000
Series C Investors
EventideLogos CapitalAsymmetry Capital ManagementOsage University PartnersSoleus Capital ManagementSands Capital VenturesHenderson Global InvestorsRA Capital ManagementDeep Track CapitalNorthpond VenturesNew Leaf Venture PartnersDriehaus Capital ManagementSeries C
$80,000,000
Series C Investors
EventideAltitude Life Science VenturesSoleus Capital ManagementSands Capital VenturesAlexandria Venture InvestmentsDriehaus Capital ManagementNew Leaf Venture PartnersAsymmetry Capital ManagementAgent CapitalOsage University PartnersSanofi VenturesRA Capital ManagementNorthpond VenturesSeries B
$40,481,981
Series B Investors
Northpond VenturesSeries Unknown
$3,999,990
Series Unknown
$2,899,925